Cost-effectiveness of first-line versus delayed use of combination dapagliflozin and metformin in patients with type 2 diabetes

The present study sought to evaluate the cost-effectiveness of first-line (immediate) versus delayed use of combination dapagliflozin and metformin in patients with type 2 diabetes, from the perspective of the Australian healthcare system. We developed a Markov model to simulate the progress of subj...

Descripción completa

Detalles Bibliográficos
Autores principales: Chin, Ken Lee, Ofori-Asenso, Richard, Si, Si, Hird, Thomas R., Magliano, Dianna J., Zoungas, Sophia, Liew, Danny
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397228/
https://www.ncbi.nlm.nih.gov/pubmed/30824788
http://dx.doi.org/10.1038/s41598-019-40191-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6397228/
https://www.ncbi.nlm.nih.gov/pubmed/30824788
http://dx.doi.org/10.1038/s41598-019-40191-8

Ejemplares similares